Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?
Video navigation menu
- Classification of CKD and CKD-associated CV risk 00:33
- A case presentation of a CKD patient with diabetes 02:11
- A paradigm change in nephrology 04:45
- Clinical concerns with SGLT2i - the eGFR dip 06:31
- New trials with a primary cardio-renal composite outcome 11:24
What is true about patients with an eGFR dip >10% after initiating empagliflozin?
- A. They have worse outcomes compared to non-dippers
- B. Their eGFR stabilizes after 12 weeks
- C. After discontinuation of empagliflozin, their eGFR remains stable
- D. These patients more often are on diuretic therapy and have a low KDIGO score
This lecture by Christoph Wanner was part of the EBAC-accredited symposium "Impacting cardiovascular and kidney protection in CKD: The evolving role of SGLT2i" held during the virtual ERA EDTA 2020 meeting.
Prof. Christoph Wanner, Division of Nephrology and Hypertension at the University Hospital of Würzburg, Germany.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: